<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215721</url>
  </required_header>
  <id_info>
    <org_study_id>2007-5720-2</org_study_id>
    <nct_id>NCT01215721</nct_id>
  </id_info>
  <brief_title>Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)</brief_title>
  <official_title>Vesicare™ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is the most common non-cutaneous malignancy in men and is the 2nd leading
      cause of death from cancer in men. Radical prostatectomy is one of the treatment options
      available for organ-confined disease. Over 100,000 radical prostatectomies cases (total
      removal of the cancerous prostate by surgery) are performed in the United States yearly.
      Unfortunately nearly all of the men undergoing surgery report diminished Quality of Life
      (QOL) scores due in part due to a postoperative incontinence which may require the use of
      multiple urinary pads per day. Many of these men also report debilitating irritative voiding
      symptoms of urinary urgency and frequency, and have overall decreased urinary satisfaction
      scores. Abatement of these symptoms can take up to one year in men, and in 5-20% of patients
      symptoms may persist for longer periods.

      Our recent published findings suggest that instability in the bladder muscle is likely an
      underlying etiology in postoperative urinary incontinence. This 'Detrusor Muscle' instability
      results in excess contractions of the urinary bladder ('urgency to urinate'), and can result
      in the feeling of needing to urinate more frequently. Consistent with this hypothesis of
      detrusor muscle instability, men with postoperative dribbling had more complaints with
      urgency, frequency and bother scores when queried with validated questionnaires. We suspect
      that a transient bladder muscle contraction may overcome the urinary sphincter valve
      resistance and result in the patient's dribbling of urine.

      By treating the bladder muscle instability, we expect improved postoperative continence and
      improved quality of life in patients after undergoing surgery for total removal of a
      cancerous prostate. This pilot study will assess the statistical requirements for the number
      of subjects needed for a fully 'powered' randomized prospective study to fully evaluate
      whether medications such as solifenacin significantly improve patients' quality of urinary
      life and improve postoperative urinary incontinence after surgery.

      *This study has been modified from the original protocol with the clinicaltrials.gov ID:
      NCT00581061.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Continence</measure>
    <time_frame>12 months</time_frame>
    <description>Days to zero pad continence were assessed by patient self-reported Pad free continence declaration card.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Vesicare</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vesicare 5mg daily for 90 days was prescribed for men presenting with post-Robotic Assisted Radical Prostatectomy (RARP) severe incontinence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vesicare</intervention_name>
    <description>5 mg daily</description>
    <arm_group_label>Vesicare</arm_group_label>
    <other_name>Vesicare (Solifenacin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients that have been diagnosed with prostate cancer and will undergo treatment for
             the disease as part of standard clinical care

          -  Patients that have multiple pad use a few days after standard of care catheter removal

        Exclusion Criteria:

          -  Contra-indication to Solifenacin

          -  Narrow angle glaucoma

          -  Hepatic impairment

          -  Renal impairment

          -  CYP3A4 inhibitors (e.g. Ketoconazole)

          -  Gastric Retention (delayed or slow emptying of the stomach)

          -  Lives in a different country
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Ahlering, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://urology.uci.edu/prostate/</url>
    <description>Robotic Prostatectomy | Thomas Ahlering, M.D. | Department of Urology</description>
  </link>
  <link>
    <url>http://www.urology.uci.edu</url>
    <description>Department of Urology | University of California, Irvine</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <results_first_submitted>December 4, 2013</results_first_submitted>
  <results_first_submitted_qc>December 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 23, 2014</results_first_posted>
  <last_update_submitted>December 4, 2013</last_update_submitted>
  <last_update_submitted_qc>December 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Thomas E. Ahlering</investigator_full_name>
    <investigator_title>Urology Account Contact</investigator_title>
  </responsible_party>
  <keyword>Incontinence</keyword>
  <keyword>Robotic Prostatectomy</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants are limited to men undergoing a robot assistered radical prostatectomy at the University of California, Irvine.</recruitment_details>
      <pre_assignment_details>Only men who at the 6th or 7th day post-catheter removal are multiple pad users (3 pads or more) will be invited to participate in this trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vesicare</title>
          <description>Vesicare™ (Solifenacin) : 5 mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Population: Men presenting with urinary incontinence requiring 3 pads or more at post-catheter day 6 or 7 after RARP (robotic assisted radical prostatectomy).</population>
      <group_list>
        <group group_id="B1">
          <title>Vesicare</title>
          <description>Vesicare™ (Solifenacin) : 5 mg daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Severely Incontinent Men Post RARP</title>
          <description>Only men who were experiencing severe incontinence were screened for possible enrollment on to the study. Men who were utilizing 3 or more pads at post-catheter day 6 or 7 were deemed severely incontinent, and were invited to participate int he trial.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Continence</title>
        <description>Days to zero pad continence were assessed by patient self-reported Pad free continence declaration card.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vesicare, 5mg Treatment Group</title>
            <description>Vesicare™ (Solifenacin) : 5 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Continence</title>
          <description>Days to zero pad continence were assessed by patient self-reported Pad free continence declaration card.</description>
          <units>Days to Continence</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" spread="128.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for the duration of 3 months from the time of medication administration.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vesicare, 5mg Treatment Group</title>
          <description>Vesicare™ (Solifenacin) : 5 mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach Cramps</sub_title>
                <description>The patient was dehydrated while on the Vesicare medication, and as a result, suffered from a an episode of intense abdominal pain and constipation. The patient stopped taking the study medication and was not hospitalized.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Faintness, Flushing</sub_title>
                <description>This patient was concomitantly taking the study medication Vesicare in addition to Viagra (Sildenafil citrate). During dinner the patient suffered shock, faintness, and flushing. The patient did visit the emergency room.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One limitation of this study was finding a reasonable Control group. This is problematic as symptoms that definitively identify detrusor overactivity preoperatively don’t exist; hence we used pad usage 7 dys post catheter removal as a surrogate.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas Ahlering, MD</name_or_title>
      <organization>UC Irvine</organization>
      <phone>714-456-6068</phone>
      <email>tahlerin@uci.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

